Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD +2.57%15 Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 1,012 Drug Manufacturers companies, Galderma Group AG ranks worse than 56.72% on this metric.
Galderma Group AG's Enterprise Value for the quarter that ended in Jun. 2026 was CHF44,384 Mil.
Galderma Group AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF876 Mil. Galderma Group AG's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for Galderma Group AG's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSWX:GALD'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1.45 Med: 2.01 Max: 2.95
Current: 2.08
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Galderma Group AG was 2.95%. The lowest was 1.45%. And the median was 2.01%.
XSWX:GALD's Earnings Yield (Joel Greenblatt) % is ranked worse than 56.72% of 1012
companies
in the Drug Manufacturers industry
Industry Median: 3.32
vs XSWX:GALD: 2.08
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Galderma Group AG's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Galderma Group AG (XSWX:GALD) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Galderma Group AG Earnings Yield (Joel Greenblatt) % Related Terms
Galderma Group AG Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Earnings Yield (Joel Greenblatt) % falls into.
Galderma Group AG Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Galderma Group AGs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Galderma Group AG (XSWX:GALD) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Galderma Group AG and its competitors. Over the past decade, Galderma Group AG's Earnings Yield (Joel Greenblatt) % has ranged from 1.45 to 2.95. According to the industry distribution chart, Galderma Group AG ranks #574 out of 1012 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is Galderma Group AG's Earnings Yield (Joel Greenblatt) % too high?
Galderma Group AG's current Earnings Yield (Joel Greenblatt) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 2.95. Based on the distribution chart, Galderma Group AG ranks #574 out of 1012 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #574 out of 1012 companies for Earnings Yield (Joel Greenblatt) %. This places Galderma Group AG in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.32. Historically, Galderma Group AG's own Earnings Yield (Joel Greenblatt) % has ranged from 1.45 to 2.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.32, based on 1,012 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Earnings Yield (Joel Greenblatt) % of 0.00%. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
